Nebiretic (Hydrochlorothiazide, Nebivolol)

Hydrochlorothiazide and Nebivolol, the active ingredients in Nebiretic, are a thiazide diuretic and a beta‑blocker presented as oral tablets for systemic use. They treat hypertension in adult patients. GNH USA supplies Nebiretic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebiretic, a combination of a thiazide diuretic and a beta‑blocker, is used to manage hypertension.

- Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events.

Nebiretic may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Sexual dysfunction

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute gout attacks - Pancreatitis - Marked hypotension - Anaphylactic or severe allergic reactions - Renal function impairment

Before initiating Nebiretic, clinicians should consider several safety measures.

- Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function assessment: adjust therapy in patients with impaired kidney function. - Electrolyte surveillance: watch for hypokalemia or hyponatremia. - Diabetes caution: monitor blood glucose as diuretics may affect glycemic control. - Concomitant β‑blocker use: avoid abrupt discontinuation to prevent rebound tachycardia. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nebiretic can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Lithium: increased risk of lithium toxicity. - NSAIDs: may blunt diuretic effect and worsen renal function. - ACE inhibitors or ARBs: heightened risk of hyperkalemia and renal impairment. - Other diuretics: can cause excessive fluid loss and electrolyte disturbances. - CYP2D6 inhibitors: may increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: diuretic‑induced changes in glucose may require dose adjustment. - Calcium channel blockers: additive blood‑pressure‑lowering effect. - Warfarin: possible alteration of INR values. - Digoxin: enhanced risk of bradycardia. - Alcohol: may increase hypotensive effect.